TAG and TB CAB send letter to FDA and to the EMA to encourage crucial regulatory harmonization on endpoints for tuberculosis drug development, and to encourage Otsuka and Janssen to conduct necessary drug-drug interaction studies on bedaquiline and delamanid.
May 24, 2012 TO: Marco Cavaleri CC: Hans-Georg Eichler European Medicines Agency 7 Westferry Circus- Canary Whar London E14 4 HB United Kingdom RE: Conducting drug-drug interaction studies for bedaquiline (TMC207) and delamanid (OPC6783) Dear Dr. Cavaleri, We wish to draw…
TAG has previously expressed opposition to the PAVE100A vaccine trial involving the Vaccine Research Center’s DNA and Ad5 candidate(i). With the recent presentation by Dan Barouch of new macaque challenge data involving a DNA/adenovirus prime-boost regimen at the 2009 Keystone meeting(ii), we now must vociferously oppose the proposed descendant of PAVE100A, the HVTN 505 trial.
TAG and the TB CAB send open letter to Cepheid calling for price reduction for the GeneXpert machines and the Xpert MTB/RIF cartridges.
TAG and the TB CAB support South African advocates, doctors, and organizations in their call for early access to bedaquiline by sending an open letter to the South African Medicines Control Council (MCC).
As representatives of organizations that advocate for an evidence-based and robust response to global AIDS, we respond to your fiscal year 2013 budget request for the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR)—the flagship bilateral AIDS program—with shock and dismay.
Letter sent in response to the press release issued by Sangamo BioSciences on January 9th 2012, the undersigned individuals and organizations are writing to express concern about the status of the SB-728-T development program.
TAG and other partner organizations issued this letter about their serious and unresolved concerns about the proposed clinical trial comparing stavudine at 20 mg to tenofovir.
A follow up to the letter of May 3, 2011, regarding the steps being taken by the Coordinating Board to reduce the conflict of interest in the Stop TB Partnership’s relationship with the World Health Organization (WHO), improve transparency and accountability in the operations and activities of the Partnership, and strengthen the Partnership’s ability to fulfill its mandate.
TAG and other faith, labor, environmental, health, education, and development organizations sent this letter to President Barack Obama urging him to support a miniscule tax on speculative financial transactions.